Gefitinib (Iressa, ZD1839) is one of the epidermal growth factor receptor (EGFR) inhibitors approved for the treatment of advanced non-small cell lung cancer. The cutaneous reactions to EGFR inhibitors manifest as a follicular eruption, nail toxicity, xerosis, or desquamation. These adverse events, if not properly managed, can interfere with activities of daily living. We report a case of paronychia induced by gefitinib successfully treated with cryosurgery which is a simple and safe treatment.